– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results